Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REBUILD-1: Galcanezumab in Children and Adolescents with Episodic Migraine
jRCT2031200253Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial in episodic migraine comparing Galcanezumab with Placebo (2 arms). Primary endpoint: Change from baseline in the number of monthly migraine headache days at 3 months. Started Dec 2020; status: active, not recruiting.
02
Drugs
galcanezumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on jRCT2031200253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200253.